CohBar Investor Presentation — February 2021

Document content

Stellar Science, Breakthrough Medicine

February 24, 2021Developing Next -Generation

Epigenetic Treatments for

Corporate Presentation2

This presentation contains forward -looking statements within the meaning of The Private Securities Litigation Reform Act of

1995 thatinvolve substantial risks and uncertainties, including statements regarding the implications of preliminary or interim clinical data, the

Company’s plans, strategies and prospects for its business and statements regarding the development status of the Company’s

product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,”

“project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all

forward-looking statements contain these identifying words. Any forward -looking statements are based on management’s current

expectations of future events and are subject toa number of risks and uncertainties that could cause actual results to differ m aterially and

adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but ar e not limited to,

risks associated with the Company’s ability to: obtain and maintain necessary approvals from the FDA and other regulatory author ities;

continue to advance its product candidates in clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the final

results of the trial; replicate in later clinical trials positive results found in preclinical studies and early -stage clinical trials of pelabresib (CPI -

0610), CPI -0209 and CPI -482; advance the development of its product candidates under the timelines it anticipates, or at all, in current and

future clinical trials; obtain, maintain, or protect intellectual property rights related to its product candidates; manage expe nses; raise

thesubstantial additional capital needed to achieve its business objectives; and the COVID -19 pandemic and general economic and market

conditions. CPI -0610, CPI -0209 and CPI -482 are investigational therapies and have not been approved by the FDA (or any other regulatory

authority). For a discussion of other risks and uncertainties, any of which could cause the Company’s actual results to differ f rom those

contained in the forward -looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertai nties, and other

important factors, in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s Ann ual